Does simvastatin attenuate formalin-induced nociceptive behaviors by inhibiting microglial RhoA and p38 MAPK activation?
Our novel findings indicated that simvastatin attenuated formalin-induced nociceptive responses by inhibiting microglial RhoA and p38 mitogen-activated protein kinase activation. Inactivation of RhoA-p38 signaling pathway may be a pharmacologic target for treating microglia-directed central nervous system inflammation and chronic pain conditions.
Our findings support the role of MC3R genetic variants in adiposity gain during early childhood.